Breaking Finance News

RBC Capital Markets recorded RA Pharmaceuticals (NDAQ:RARX), raising its target price to $21.00 today

RA Pharmaceuticals (NDAQ:RARX) had its stock price target increased to $21.00 by RBC Capital Markets in an issued report issued 09/15/2017. The upped price target implies a possible upside of 0.37% based on the company's most recent stock price close.

On 4/19/2017, Credit Suisse released a statement for RA Pharmaceuticals (NDAQ:RARX) bumped up the target price from $0.00 to $19.00 that suggested a downside of -0.18%.

Boasting a price of $15.32, RA Pharmaceuticals (NDAQ:RARX) traded 2.37% higher on the day. With the last stock price close down -15.61% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. RA Pharmaceuticals has recorded a 50-day average of $14.33 and a two hundred day average of $17.93. Volume of trade was down over the average, with 64,252 shares of RARX changing hands under the typical 109,225

Performance Chart

RA Pharmaceuticals (NDAQ:RARX)

With a total market value of $0, RA Pharmaceuticals has with a one year low of $12.05 and a one year high of $24.12 .

Brief Synopsis About RA Pharmaceuticals (NDAQ:RARX)

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *